Psychedelic

Order to speed hallucinogen research hailed as ‘threshold moment’ but concerns remain over access and protectionsThe scene seemed so far-fetched you could be forgiven for thinking you might be hallucinating.On the weekend in which psychonauts celebrate “Bicycle Day” – the anniversary of the first LSD trip – Donald Trump was in the Oval Office double-checking that he was correctly pronouncing the name of a lesser-known psychedelic, ibogaine, as he signed a landmark executive order to accelerate research into hallucinogens, and to increase access. Continue reading...

Use of the illicit drug has plummeted in recent years among gen Zers, compared with their parents’ generationEver since cocaine first emerged as a popular party drug via the shores of Miami in the early 1970s, use of the stimulant has been inextricably entwined with the very essence of capitalist excess and what it is to be American: brash, bombastic and brazen.The wide-scale use of cocaine in the US has left a trail of destruction in its wake, largely thanks to the illegal nature of the trade and the resultant US government policy of a “war on drugs”. Continue reading...

• President Trump has moved to fast-track psychedelic research as part of his administration's policy agenda, marking a significant shift in federal drug policy priorities. • Former Arizona Senator Kyrsten Sinema has publicly applauded the initiative as a "bold step forward" in medical research on Fox & Friends Weekend. • The accelerated psychedelic research program represents an innovative approach to mental health treatment and scientific advancement under the Trump administration.

• The FDA announced it will issue national priority vouchers for three psychedelic drugs next week, marking the first time the agency has fast-tracked any psychedelics for review under Trump's executive order on mental health reform. • The vouchers can compress FDA review timelines from several months to just weeks, according to FDA Commissioner Marty Makary, if the drugs align with national priorities. • Trump's order directs $50 million in federal funding to states developing psychedelic treatment programs and establishes a federal-state partnership for technical assistance and data sharing.

• President issues executive order on April 18, 2026, to speed medical treatments for serious mental illness using psychedelic drugs including ibogaine compounds. • Order highlights clinical studies showing potential for patients with persistent conditions unresponsive to standard therapies. • Directs federal agencies to prioritize research, approvals, and access to innovative mental health interventions nationwide.

President signed executive order directing FDA to expedite review of psychedelic drugs including ibogaineDonald Trump on Saturday announced reforms intended to speed up access to medical research and treatment based on psychedelic drugs.The president signed an executive order directing the federal Food and Drug Administration (FDA) to expedite review of drugs such as ibogaine, a drug that US military veteran groups have said can help treat post-traumatic stress disorder. Continue reading...

Analysis of more than 500 brain scans finds LSD, psilocybin and other psychedelics increase cross-talk between brain systemsScientists have identified a hallmark signature produced by psychedelic drugs in the human brain when users experience their mind-altering effects.The “neural fingerprint” of the psychedelic trip was spotted among hundreds of brain scans of people on LSD, psilocybin, DMT, mescaline and ayahuasca, pointing to a shared impact on the brain’s behaviour. Continue reading...